Zhi-Gang Peng (Zhigang Peng)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 7

Top Topics

Neoadjuvant Chemotherapy

Bioinformatics Analysis

Diffuse Large B Cell Lymphoma

Epstein Barr Virus

Top Venues

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Mei-Wei Li, Feng-Xiang Huang, Zu-Cheng Xie, Hao-Yuan Hong, Qing-Yuan Xu, Zhi-Gang Peng
Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B-cell lymphoma. Cancer medicine 12 (3) (2022)
Mei-Wei Li, Feng-Xiang Huang, Zu-Cheng Xie, Hao-Yuan Hong, Qing-Yuan Xu, Zhi-Gang Peng
Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B-cell lymphoma. Cancer medicine 12 (3) (2022)
Yehong Bin, Dong Lan, Wenguang Bao, Haiyan Yang, Shengsheng Zhou, Fengxiang Huang, Man Wang, Zhi-Gang Peng
SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation. Trials 23 (1) (2022)
Mei-Wei Li, Feng-Xiang Huang, Zu-Cheng Xie, Hao-Yuan Hong, Qing-Yuan Xu, Zhi-Gang Peng
Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B-cell lymphoma. Cancer medicine 12 (3) (2022)
Mei-Wei Li, Feng-Xiang Huang, Zu-Cheng Xie, Hao-Yuan Hong, Qing-Yuan Xu, Zhi-Gang Peng
Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B-cell lymphoma. Cancer medicine 12 (3) (2022)
Qing-Yuan Xu, Hai-Yan Yang, Mei-Wei Li, Zhen-Dong He, Hao-Yuan Hong, Zhi-Gang Peng
Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review. Medicine 101 (38) (2022)
Hai-Wei Liang, Bin Luo, Li-Hua Du, Rong-Quan He, Gang Chen, Zhi-Gang Peng, Jie Ma
Expression significance and potential mechanism of hypoxia-inducible factor 1 alpha in patients with myelodysplastic syndromes. Cancer medicine 8 (13) (2019)